GENLISA™ Human Anti-SARS-CoV-2 IgG Antibody to Nucleocapsid Protein ELISA (Quantitative) - CE MARKED

Available asualitative kit (ICMR approved) as well asuantitative kit (KBVH015-9-QT). Quantitative datasheet available under & ldquo; Documents& rdquo; tab.< /strong>

Introduction: The GENLISA™ ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a sandwich ELISA technique which leads to a higher specificity and increased sensitivity compared to conventional ELISA kits which employ only one antibody.

Intended Use: The GENLISA™ Human Anti-SARS-CoV-2 (Covid-19) IgG ELISA kit is used as an analytical tool for qualitative estimation of IgG antibodies to Human SARS-CoV-2 (Covid-19) nucleoproteins in human serum and plasma (K+-EDTA, Li+-heparin, Na+-citrate). The GENLISA™ Human Anti-SARS-CoV-2 ELISA (IgG) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The GENLISA™ Human Anti-SARS-CoV-2 ELISA (IgG) should not be used to diagnose acute SARS-CoV-2 infection. Testing is limited to laboratories certified under ICMR. Results are for the detection of SARS CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. Laboratories within India are required to report all positive results to the appropriate public health authorities. The sensitivity of GENLISA™ Human Anti-SARS-CoV-2 ELISA (IgG) early after infection is unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary. False positive results for the GENLISA™ Human Anti-SARS-CoV-2 ELISA (IgG) may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

Principle: The method employs sandwich ELISA technique. Human SARS-CoV-2 nucleoprotein is pre-coated onto microwells. Samples and controls are pipetted into microwells and IgG Antibodies to human SARS-CoV-2 (Covid-19) present in the sample are bound by the protein antigen.After incubation the wells are washed and followed by HRP-conjugated Detection IgG Antibody is pipetted and incubated to form a complex. After washing microwells in order to remove any non-specific binding, the substrate solution (TMB) is added to microwells and color develops proportionally to the amount of IgG AntiHuman SARS-CoV-2 (Covid-19) in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.